MRSN - NASDAQ
Mersana Therapeutics, Inc.
$29.08
+0.0000%Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotMersana Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Mersana Therapeutics, Inc. Cash Flow Statement
MRSN • NASDAQ
| Mersana Therapeutics, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||
-69.2M | -171.7M | -204.2M | -170.1M | -88M | -28.2M | -64.3M | -38.7M | -13.7M | -16.4M | |
1.6M | 1.5M | 927K | 855K | 1M | 1.2M | 1.3M | 928K | 655K | 297K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -222K | -386K | -134K | -102K | -349K | |
16.5M | 21.1M | 21.5M | 18.4M | 7.2M | 4.9M | 3.9M | 1.4M | 668K | 349K | |
-496K | -1.1M | -699K | 723K | 62K | 103K | 110K | -159K | 102K | 349K | |
(418K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-30.7M | -18.8M | 133.1M | 10.1M | 5.1M | -45.5M | 4.2M | -6M | 44M | 6.1M | |
-82.3M | -168.9M | -49.4M | -140M | -74.7M | -67.7M | -55.2M | -42.7M | 31.6M | -9.6M | |
INVESTING ACTIVITIES | ||||||||||
-132K | -2.2M | -2.2M | -648K | -473K | -605K | -1.4M | -1.1M | -1.1M | -619K | |
(0.0) | (0.0) | (150.5M) | (0.0) | (0.0) | (26.7M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-133.4M | -155.9M | -247.5M | (0.0) | (0.0) | -53.7M | (0.0) | -145.7M | (0.0) | -164K | |
145M | 278M | 97M | 0.0 | 37.5M | 27M | 88.6M | 47.2M | 0.0 | 0.0 | |
0.0 | 0.0 | -150.5M | 0.0 | 0.0 | -26.7M | 88.6M | -98.5M | 0.0 | -164K | |
(11.4M) | (119.9M) | -152.7M | -648K | (37M) | -27.3M | (87.2M) | -99.6M | -1.1M | -783K | |
FINANCING ACTIVITIES | ||||||||||
5.8M | 93.5M | 150.9M | 43.1M | 227M | 92.2M | 0.0 | 68.1M | 0.0 | 0.0 | |
-2.2M | -262K | -272K | 18.3M | -313K | 4.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (146K) | (0.0) | (0.0) | (0.0) | |
542K | 1.4M | 2.4M | 2.2M | 3.7M | 664K | 1.1M | 452K | 105K | 0.0 | |
4.1M | 94.7M | 153M | 63.6M | 230.4M | 97.7M | 1.1M | 68.6M | 58.3M | 10M | |
CASH FLOW SUMMARY | ||||||||||
-66.8M | 45.7M | -49.1M | -77M | 192.7M | 2.7M | 33M | -73.7M | 88.8M | -459K | |
175M | 129.4M | 178.4M | 255.4M | 62.7M | 60M | 27M | 100.3M | 11.5M | 12M | |
108.2M | 175M | 129.4M | 178.4M | 255.4M | 62.7M | 60M | 26.6M | 100.3M | 11.5M | |
-82.5M | -171.1M | -51.6M | -140.6M | -75.2M | -68.3M | -56.6M | -43.8M | 30.5M | -10.3M |
SEC Filings
MRSN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | January 06, 2026 | January 05, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 05, 2025 | September 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 13, 2025 | August 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 13, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 24, 2025 | July 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 03, 2025 | July 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 13, 2025 | June 12, 2025 | 2025 |
Related Guides
Continue your MRSN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.